A share price of Ocular Therapeutix Inc [OCUL] is currently trading at $7.31, up 1.95%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OCUL shares have gain 14.13% over the last week, with a monthly amount drifted -5.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $17. On March 11, 2025, Needham initiated with a Buy rating and assigned a price target of $15 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. TD Cowen upgraded its rating to a Buy and raised its price target to $11 on June 20, 2024. In a note dated February 09, 2024, BofA Securities initiated an Buy rating and provided a target price of $15 on this stock.
Ocular Therapeutix Inc experienced fluctuations in its stock price throughout the past year between $4.06 and $11.77. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $7.31 at the most recent close of the market. An investor can expect a potential return of 159.92% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Trailing Twelve Months sales for Ocular Therapeutix Inc [NASDAQ:OCUL] were 63.72M which represents 15.40% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -3.04%, and Net Profit Margin reading is -3.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.53 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.16 points at the first support level, and at 7.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.42, and for the 2nd resistance point, it is at 7.53.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ocular Therapeutix Inc [NASDAQ:OCUL] is 10.66. Also, the Quick Ratio is 10.59, while the Cash Ratio stands at 9.48. Considering the valuation of this stock, the price to sales ratio is 18.24, the price to book ratio is 3.66.
Transactions by insiders
Recent insider trading involved Dugel Pravin, that happened on Feb 24 ’25 when 21475.0 shares were sold. Chief Scientific Officer, Heier Jeffrey S. completed a deal on Feb 24 ’25 to sell 3061.0 shares. Meanwhile, Chief Development Officer Kaiser Peter sold 3009.0 shares on Feb 24 ’25.
